+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bevacizumab"

From
From
From
Ovarian Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Ovarian Cancer Drugs - Global Strategic Business Report

  • Report
  • July 2026
  • 326 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • July 2026
  • 277 Pages
  • Global
From
From
From
From
From
Bispecific Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Bispecific Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
From
Epithelial Ovarian Cancer Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Epithelial Ovarian Cancer Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Carcinoid Tumor Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Carcinoid Tumor Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Hepatic Tumor Pipeline Analysis Report 2025 - Product Thumbnail Image

Hepatic Tumor Pipeline Analysis Report 2025

  • Report
  • March 2026
  • 200 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs. Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated. Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more